目的 研究胰胆舒胶囊联合注射用生长抑素治疗重症急性胰腺炎的临床疗效。方法 选取2017年12月—2018年12月乐山市人民医院治疗的100例重症急性胰腺炎患者作为研究对象，采用随机数字表法将所有患者分为对照组和治疗组，每组各50例。对照组患者静脉滴注注射用生长抑素，将6 mg注射用生长抑素溶于100 mL生理盐水中，采用微量泵缓静滴24 h，静脉滴注速度0.25 mg/h。治疗组在对照组治疗的基础上口服胰胆舒胶囊，3粒/次，3次/d。两组患者均接受治疗14 d。观察两组患者的临床疗效，同时比较两组的临床症状缓解时间、生化指标和炎症因子水平。结果 治疗后，对照组和治疗组的总有效率分别为80.00%、94.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者腹水消失时间、腹痛消失时间、血淀粉酶恢复时间、排气恢复时间均显著短于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清淀粉酶（AMS）、血清脂肪酶（LPS）和门冬氨酸氨基转移酶（AST）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；并且治疗组生化指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的C反应蛋白（CRP）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组炎症因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 胰胆舒胶囊联合注射用生长抑素治疗重症急性胰腺炎具有较好的临床疗效，能够改善患者临床症状和生化指标水平，安全性较高，值得在临床上推广应用。

Objective To study the clinical efficacy of Yidanshu Capsules combined with Somatostatin for injection in treatment of severe acute pancreatitis. Methods Patients (100 cases) with severe acute pancreatitis in The People's Hospital of Leshan from December 2017 to December 2018 were divided into control and treatment groups according to the random number table method, and each group had 50 cases. Patients in the control group were iv administered with Somatostatin for injection, 6 mg dissolved into 100 mL normal saline, and trace mercury was used for 24 h with intravenous drip speed of 0.25 mg/h. Patients in the treatment group were po administered with Yidanshu Capsules on the basis of control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy, and clinical symptoms remission time, biochemical indexes and inflammatory factor levels in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.00% and 94.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the ascites disappearance time, abdominal pain disappearance time, blood amylase recovery time, and exhaust recovery time in the treatment group were significantly shorter than those in the control group, and there were differences between two groups (P<0.05). After treatment, AMS, LPS, and AST in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the biochemical index levels in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, levels of CRP, IL-6, and TNF-α in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the inflammatory factor levels in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Yidanshu Capsules combined with Somatostatin for injection has good clinical efficacy in treatment of severe acute pancreatitis, can improve the clinical symptoms and biochemical indexes of patients, with high safety, which has a certain clinical application value.